Efficacy, Safety, and Tolerability of Ansofaxine (Ly03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo Controlled, Dose-Finding, Phase 2 Clinical Trial

Extended Release ◽

Dose Finding ◽

Phase 2 ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Clinical Trial ◽

Extended Release Tablet

Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder

Journal of Affective Disorders ◽

10.1016/j.jad.2021.02.027 ◽

2021 ◽

Vol 285 ◽

pp. 112-119

Author(s):

Alix Arnaud ◽

Ellison Suthoff ◽

Katie Stenson ◽

Brian Werneburg ◽

Paul Hodgkins ◽

...

Keyword(s):

Clinical Trial ◽

Depressive Disorder ◽

Number Needed To Treat ◽

Phase 2 ◽

Major Depressive ◽

Phase 2 Clinical Trial ◽

Clinical Trial Results ◽

Number Needed To Harm

447-P: The Efficacy and Safety Trial of ENERGI-F703 in Diabetic Wound Healing: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial

Diabetes ◽

10.2337/db21-447-p ◽

2021 ◽

Vol 70 (Supplement 1) ◽

pp. 447-P

Author(s):

GUANG-HUAR YOUNG ◽

JIUN-TSAI LIN ◽

YI-FANG CHENG ◽

HAN-MIN CHEN ◽

CHUN-FANG HUANG

Keyword(s):

Clinical Trial ◽

Wound Healing ◽

Diabetic Wound ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Clinical Trial ◽

Diabetic Wound Healing

Effect of prebiotic and probiotic supplementation on circulating pro-inflammatory cytokines and urinary cortisol levels in patients with major depressive disorder: A double-blind, placebo-controlled randomized clinical trial

Journal of Functional Foods ◽

10.1016/j.jff.2018.11.041 ◽

2019 ◽

Vol 52 ◽

pp. 596-602 ◽

Cited By ~ 9

Author(s):

Asma Kazemi ◽

Ahmad Ali Noorbala ◽

Kamal Azam ◽

Kurosh Djafarian

Keyword(s):

Clinical Trial ◽

Depressive Disorder ◽

Inflammatory Cytokines ◽

Urinary Cortisol ◽

Major Depressive ◽

Probiotic Supplementation ◽

Double Blind ◽

Double Blind Placebo ◽

Pro Inflammatory Cytokines

Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan

Neuropsychiatric Disease and Treatment ◽

10.2147/ndt.s146428 ◽

2018 ◽

Vol Volume 14 ◽

pp. 1261-1272 ◽

Cited By ~ 2

Author(s):

Yoshinori Watanabe ◽

Yuko Asami ◽

Yoko Hirano ◽

Kazuhiko Kuribayashi ◽

Rio Itamura ◽

...

Keyword(s):

Depressive Disorder ◽

Extended Release ◽

Controlled Study ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Subgroup Analyses ◽

Post Hoc

Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial

PEDIATRICS ◽

10.1542/peds.2018-2420ccc ◽

2018 ◽

Vol 142 (Supplement 4) ◽

pp. S242.1-S242 ◽

Cited By ~ 1

Author(s):

Veena Agusala ◽

Brooke I. Polk ◽

Chitra Dinakar

Keyword(s):

Clinical Trial ◽

Peanut Allergy ◽

Oral Immunotherapy ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

AB0629 Design of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of The Toll-like Receptor Antagonist IMO-8400 in Patients with Dermatomyositis

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.5174 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 1119.2-1119 ◽

Cited By ~ 2

Author(s):

P. Gordon ◽

R. Cooper ◽

H. Chinoy ◽

D. Isenberg ◽

I.E. Lundberg ◽

...

Keyword(s):

Clinical Trial ◽

Receptor Antagonist ◽

Phase 2 ◽

Toll Like Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial

The Journal of Allergy and Clinical Immunology In Practice ◽

10.1016/j.jaip.2017.09.016 ◽

2018 ◽

Vol 6 (2) ◽

pp. 476-485.e3 ◽

Cited By ~ 73

Author(s):

J. Andrew Bird ◽

Jonathan M. Spergel ◽

Stacie M. Jones ◽

Rima Rachid ◽

Amal H. Assa'ad ◽

...

Keyword(s):

Clinical Trial ◽

Peanut Allergy ◽

Oral Immunotherapy ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder

Journal of Clinical Psychopharmacology ◽

10.1097/jcp.0000000000000060 ◽

2014 ◽

Vol 34 (1) ◽

pp. 47-56 ◽

Cited By ~ 43

Author(s):

Angelo Sambunaris ◽

Anjana Bose ◽

Carl P. Gommoll ◽

Changzheng Chen ◽

William M. Greenberg ◽

...

Keyword(s):

Depressive Disorder ◽

Extended Release ◽

Phase Iii ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Study ◽

Flexible Dose

Antidepressants effects of Rhodiola capsule combined with sertraline for major depressive disorder: A randomized double-blind placebo-controlled clinical trial

Journal of Affective Disorders ◽

10.1016/j.jad.2020.01.065 ◽

2020 ◽

Vol 265 ◽

pp. 99-103

Author(s):

Lili Gao ◽

Chenghan Wu ◽

Yuansheng Liao ◽

Jinmin Wang

Keyword(s):

Clinical Trial ◽

Depressive Disorder ◽

Controlled Clinical Trial ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Faculty Opinions recommendation of EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718270683.793501691 ◽

2014 ◽

Author(s):

Nanna Finnerup

Keyword(s):

Clinical Trial ◽

Angiotensin Ii ◽

Receptor Antagonist ◽

Postherpetic Neuralgia ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Novel Treatment ◽